Feature | August 23, 2010

European Distribution Agreement for Radiation Therapy System Signed

August 23, 2010 - Calypso Medical Technologies Inc., entered into a distribution agreement with Siemens Healthcare for the sale of its Calypso System in Europe.

The Calypso System is a real-time localization technology used for the precise tracking of tumor targets.

“This agreement extends the availability of our GPS for the Body technology into geographic areas with significant incidences of prostate cancer," said Jed Palmacci, vice president of global sales for Calypso Medical.

Under terms of the agreement, Siemens retains nonexclusive rights to sell Calypso’s real-time tracking technology to existing and prospective Siemens linear accelerator customers throughout Europe for a period of three years.

Last year Calypso Medical entered into a master development agreement (MDA) with Siemens to jointly develop products integrating the Calypso System with the Siemens ARTISTE linear accelerator and other Siemens radiotherapy technologies.

With recent clinical findings of improved outcomes, Calypso's GPS for the Body technology enables doctors to localize and track the tumor before and during each radiation treatment. When the tumor moves outside of the field of radiation, therapy can be stopped while the patient is repositioned to ensure that the tumor, not surrounding healthy tissue, receives the radiation dose.

In contrast to other tumor targeting solutions, the Calypso System provides continuous tumor position information, objectively and without ionizing radiation, thereby safeguarding the patient from an additional nontherapeutic radiation dose.

For more information: www.calypsomedical.com, www.siemens.com/healthcare

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...